ARID3B increases ovarian tumor burden and is associated with a cancer stem cell gene signature

Oncotarget

Volumn 5, Issue 18, 2014, Pages 8355-8366

  Roy, Lynn ^a   Samyesudhas, Serene J ^a   Carrasco, Martin ^a   Li, Jun ^b   Joseph, Stancy ^a   Dahl, Richard ^a   Cowden Dahl, Karen D ^a,b,c  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF NOTRE DAME   (United States)

^c INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cancer stem cells; Metastasis; Ovarian cancer; Transcription factor; Xenografts

Indexed keywords

DNA BINDING PROTEIN; PACLITAXEL; ANTINEOPLASTIC AGENT; ARID3B PROTEIN, HUMAN; CD133 ANTIGEN; GLYCOPROTEIN; LEUKOCYTE ANTIGEN; PEPTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARID3B GENE; ARTICLE; ASCITES TUMOR; CANCER GROWTH; CANCER STEM CELL; CARCINOGENESIS; CD44 GENE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; HUMAN; IN VIVO STUDY; LGR5 GENE; METASTASIS; MOUSE; NONHUMAN; NOTCH2 GENE; ONCOGENE; OVARY CANCER; PROM1 GENE; TUMOR GROWTH; TUMOR VOLUME; ANIMAL; CELL ADHESION; CELL MOTION; CELL PROLIFERATION; DISEASE COURSE; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETIC TRANSFECTION; GENETICS; METABOLISM; NUDE MOUSE; OVARIAN NEOPLASMS; PATHOLOGY; PROCEDURES; SIGNAL TRANSDUCTION; TIME; TUMOR CELL LINE; TUMOR INVASION;

ANIMALS; ANTIGENS, CD; ANTINEOPLASTIC AGENTS; CELL ADHESION; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; DISEASE PROGRESSION; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOPROTEINS; HUMANS; MICE, NUDE; NEOPLASM INVASIVENESS; NEOPLASTIC STEM CELLS; OVARIAN NEOPLASMS; PACLITAXEL; PEPTIDES; SIGNAL TRANSDUCTION; TIME FACTORS; TRANSFECTION; TUMOR BURDEN; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84907967536     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.2247     Document Type: Article

References (33)

1. Pennington K, Pulaski H, Pennington M and Liu JR. Too Much of a Good Thing: Suicide Prevention Promotes Chemoresistance in Ovarian Carcinoma. Curr Cancer Drug Targets. 2010.
2. Albini A, Cesana E and Noonan DM. Cancer stem cells and the tumor microenvironment: soloists or choral singers. Curr Pharm Biotechnol. 2011; 12(2):171-181.
3. Bapat SA, Mali AM, Koppikar CB and Kurrey NK. Stem and progenitor-like cells contribute to the aggressive behavior of human epithelial ovarian cancer. Cancer research. 2005; 65(8):3025-3029.
4. Di J, Duiveman-de Boer T, Zusterzeel PL, Figdor CG, Massuger LF and Torensma R. The stem cell markers Oct4A, Nanog and c-Myc are expressed in ascites cells and tumor tissue of ovarian cancer patients. Cellular oncology. 2013; 36(5):363-374.
5. Hu L, McArthur C and Jaffe RB. Ovarian cancer stem-like side-population cells are tumourigenic and chemoresistant. British journal of cancer. 2010; 102(8):1276-1283.
6. Latifi A, Luwor RB, Bilandzic M, Nazaretian S, Stenvers K, Pyman J, Zhu H, Thompson EW, Quinn MA, Findlay JK and Ahmed N. Isolation and characterization of tumor cells from the ascites of ovarian cancer patients: molecular phenotype of chemoresistant ovarian tumors. PloS one. 2012; 7(10):e46858.
7. Luo L, Zeng J, Liang B, Zhao Z, Sun L, Cao D, Yang J and Shen K. Ovarian cancer cells with the CD117 phenotype are highly tumorigenic and are related to chemotherapy outcome. Experimental and molecular pathology. 2011; 91(2):596-602.
8. Meng E, Long B, Sullivan P, McClellan S, Finan MA, Reed E, Shevde L and Rocconi RP. CD44+/CD24-ovarian cancer cells demonstrate cancer stem cell properties and correlate to survival. Clinical & experimental metastasis. 2012; 29(8):939-948.
9. Rizzo S, Hersey JM, Mellor P, Dai W, Santos-Silva A, Liber D, Luk L, Titley I, Carden CP, Box G, Hudson DL, Kaye SB and Brown R. Ovarian cancer stem cell-like side populations are enriched following chemotherapy and overexpress EZH2. Molecular cancer therapeutics. 2011; 10(2):325-335.
10. Vathipadiekal V, Saxena D, Mok SC, Hauschka PV, Ozbun L and Birrer MJ. Identification of a potential ovarian cancer stem cell gene expression profile from advanced stage papillary serous ovarian cancer. PloS one. 2012; 7(1):e29079.
11. Yang L and Lai D. Ovarian cancer stem cells enrichment. Methods in molecular biology. 2013; 1049:337-345.
12. Ferrandina G, Bonanno G, Pierelli L, Perillo A, Procoli A, Mariotti A, Corallo M, Martinelli E, Rutella S, Paglia A, Zannoni G, Mancuso S and Scambia G. Expression of CD133-1 and CD133-2 in ovarian cancer. International journal of gynecological cancer: official journal of the International Gynecological Cancer Society. 2008; 18(3):506-514.
13. Baba T, Convery PA, Matsumura N, Whitaker RS, Kondoh E, Perry T, Huang Z, Bentley RC, Mori S, Fujii S, Marks JR, Berchuck A and Murphy SK. Epigenetic regulation of CD133 and tumorigenicity of CD133+ ovarian cancer cells. Oncogene. 2009; 28(2):209-218.
14. Wilsker D, Patsialou A, Dallas PB and Moran E. ARID proteins: a diverse family of DNA binding proteins implicated in the control of cell growth, differentiation, and development. Cell Growth Differ. 2002; 13(3):95-106.
15. Joseph S, Deneke VE and Cowden Dahl KD. ARID3B Induces Tumor Necrosis Factor Alpha Mediated Apoptosis While a Novel ARID3B Splice Form Does Not Induce Cell Death. PloS one. 2012; 7(7):e42159.
16. Kobayashi K, Era T, Takebe A, Jakt LM and Nishikawa S. ARID3B induces malignant transformation of mouse embryonic fibroblasts and is strongly associated with malignant neuroblastoma. Cancer research. 2006; 66(17):8331-8336.
17. Kobayashi K, Jakt LM and Nishikawa SI. Epigenetic regulation of the neuroblastoma genes, Arid3b and Mycn. Oncogene. 2012.
18. Wang J, Rao S, Chu J, Shen X, Levasseur DN, Theunissen TW and Orkin SH. A protein interaction network for pluripotency of embryonic stem cells. Nature. 2006; 444(7117):364-368.
19. Cowden Dahl KD, Dahl R, Kruichak JN and Hudson LG. The epidermal growth factor receptor responsive miR-125a represses mesenchymal morphology in ovarian cancer cells. Neoplasia. 2009; 11(11):1208-1215.
20. Yu D, Wolf JK, Scanlon M, Price JE and Hung MC. Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A. Cancer research. 1993; 53(4):891-898.
21. Kim D, Probst L, Das C and Tucker PW. REKLES is an ARID3-restricted multifunctional domain. The Journal of biological chemistry. 2007; 282(21):15768-15777.
22. Cheon DJ, Tong Y, Sim MS, Dering J, Berel D, Cui X, Lester J, Beach JA, Tighiouart M, Walts AE, Karlan BY and Orsulic S. A collagen-remodeling gene signature regulated by TGF-beta signaling is associated with metastasis and poor survival in serous ovarian cancer. Clinical cancer research: an official journal of the American Association for Cancer Research. 2014; 20(3):711-723.
23. Giampieri R, Scartozzi M, Loretelli C, Piva F, Mandolesi A, Lezoche G, Del Prete M, Bittoni A, Faloppi L, Bianconi M, Cecchini L, Guerrieri M, Bearzi I and Cascinu S. Cancer stem cell gene profile as predictor of relapse in high risk stage II and stage III, radically resected colon cancer patients. PloS one. 2013; 8(9):e72843.
24. Yu PN, Yan MD, Lai HC, Huang RL, Chou YC, Lin WC, Yeh LT and Lin YW. Downregulation of miR-29 contributes to cisplatin resistance of ovarian cancer cells. International journal of cancer Journal international du cancer. 2014; 134(3):542-551.
25. Yasui W, Oue N, Aung PP, Matsumura S, Shutoh M and Nakayama H. Molecular-pathological prognostic factors of gastric cancer: a review. Gastric cancer: official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association. 2005; 8(2):86-94.
26. Hombach-Klonisch S, Paranjothy T, Wiechec E, Pocar P, Mustafa T, Seifert A, Zahl C, Gerlach KL, Biermann K, Steger K, Hoang-Vu C, Schulze-Osthoff K and Los M. Cancer stem cells as targets for cancer therapy: selected cancers as examples. Archivum immunologiae et therapiae experimentalis. 2008; 56(3):165-180.
27. Ford CE, Jary E, Ma SS, Nixdorf S, Heinzelmann-Schwarz VA and Ward RL. The Wnt Gatekeeper SFRP4 Modulates EMT, Cell Migration and Downstream Wnt Signalling in Serous Ovarian Cancer Cells. PLoS One. 2013; 8(1):e54362.
28. Cobaleda C, Perez-Caro M, Vicente-Duenas C and Sanchez-Garcia I. Function of the zinc-finger transcription factor SNAI2 in cancer and development. Annual review of genetics. 2007; 41:41-61.
29. Zhang S, Balch C, Chan MW, Lai HC, Matei D, Schilder JM, Yan PS, Huang TH and Nephew KP. Identification and characterization of ovarian cancer-initiating cells from primary human tumors. Cancer research. 2008; 68(11):4311-4320.
30. Steg AD, Bevis KS, Katre AA, Ziebarth A, Dobbin ZC, Alvarez RD, Zhang K, Conner M and Landen CN. Stem cell pathways contribute to clinical chemoresistance in ovarian cancer. Clin Cancer Res. 2012; 18(3):869-881.
31. Latifi A, Abubaker K, Castrechini N, Ward AC, Liongue C, Dobill F, Kumar J, Thompson EW, Quinn MA, Findlay JK and Ahmed N. Cisplatin treatment of primary and metastatic epithelial ovarian carcinomas generates residual cells with mesenchymal stem cell-like profile. J Cell Biochem. 2011; 112(10):2850-2864.
32. Ma L, Lai D, Liu T, Cheng W and Guo L. Cancer stem-like cells can be isolated with drug selection in human ovarian cancer cell line SKOV3. Acta Biochim Biophys Sin (Shanghai). 2010; 42(9):593-602.
33. Wu XS, Xi HQ and Chen L. Lgr5 is a potential marker of colorectal carcinoma stem cells that correlates with patient survival. World journal of surgical oncology. 2012; 10:244.